Fact-checked by Grok 2 weeks ago

BioLegend

BioLegend is a biotechnology company that develops and manufactures high-quality antibodies, reagents, and tools for life science research, with a focus on immunology, cell biology, neuroscience, cancer research, and stem cell studies. Founded in June 2002 in San Diego, California, by Gene Lay, D.V.M.—who also co-founded the earlier immunology firm PharMingen—the company began by producing purified and fluorophore-conjugated monoclonal antibodies to address needs in flow cytometry and related applications. Its headquarters and primary manufacturing facility remain in San Diego, with additional research and development sites in Taiwan and Japan, supporting Revvity's global operations serving customers in over 190 countries. In September 2021, BioLegend was acquired by for $5.25 billion, becoming a key part of the company's life sciences portfolio; later rebranded to in 2023, integrating BioLegend into its broader mission of advancing health sciences from discovery to diagnostics and therapeutics. As of 2024, under , BioLegend employs approximately 665 people and continues to innovate through product licensing, collaborations, and in-house hybridoma development, while maintaining :2016 certification for . The company's product portfolio includes fluorochrome-conjugated antibodies for multiparameter , kits for and multiplex assays, proteins, peptides, and detection reagents, enabling breakthroughs in biomarker identification, imaging, and across academic, biotech, and pharmaceutical sectors. BioLegend emphasizes superior customer support, competitive pricing, and rapid innovation, such as its co-development of Brilliant Violet dyes in 2011, to accelerate scientific discovery.

Overview

Company Description

BioLegend is a biotechnology company specializing in the development and manufacture of high-quality antibodies and reagents for life science research, with a particular emphasis on immunology, cell biology, neuroscience, cancer research, and stem cell studies. Headquartered with primary manufacturing in its state-of-the-art facility in San Diego, California, and additional research and development sites in Taiwan and Japan, the company—now part of Revvity—produces cutting-edge tools essential for advancing scientific understanding in these fields and serves customers in over 190 countries. It employs approximately 665 people (as of 2024). The core mission of BioLegend is to accelerate biomedical leading to cures for disease by providing innovative, high-quality products that enable legendary discoveries from to application. As of 2025, its portfolio includes over 34,000 antibodies and reagents, offering researchers a comprehensive selection for experiments in , , and other techniques. BioLegend serves key target markets including academic institutions, pharmaceutical and R&D, and clinical applications such as development. To ensure reliability and reproducibility, its products are manufactured in an ISO 13485:2016-certified facility, adhering to stringent standards.

Ownership and Leadership

In September 2021, acquired BioLegend for approximately $5.25 billion in a combination of cash and stock, positioning the deal as a transformative expansion into the life sciences sector with a focus on antibodies and reagents. The acquisition integrated BioLegend into 's portfolio, enabling synergies in research tools and diagnostics while preserving its operational focus on reagents. In April 2023, PerkinElmer rebranded to Revvity to emphasize its dedication to health science solutions, with BioLegend maintained as a distinct brand and product line within Revvity's life sciences division. This structure allows BioLegend to operate semi-autonomously as of 2025, concentrating on research and development initiatives while accessing Revvity's broader resources in multi-omics and global distribution. BioLegend was founded in 2002 by Gene Lay, D.V.M., who has served as its President and CEO since 2003 and remains a key figure post-acquisition, guiding strategic direction. The executive team, including leaders such as Vice President of Human Resources Kim Clark and General Counsel Jim Schindler, upholds BioLegend's iACT culture, which promotes innovation, aspiration, collaboration, and transformation to drive employee empowerment and product advancement. Post-acquisition integration has fostered strategic synergies, with BioLegend expected, at the time of acquisition, to contribute approximately $380 million in annual revenue to (2021 estimate), supporting expansion into diagnostics and applications through combined expertise in reagents and health solutions. These efforts enhance 's portfolio by leveraging BioLegend's high-growth tools alongside the parent company's diagnostic platforms.

History

Founding and Early Development

BioLegend was founded in June 2002 in , , by Gene Lay, D.V.M., a co-founder of PharMingen, a pioneering antibody company specializing in immunological reagents that had been acquired by Becton Dickinson (now BD Biosciences) in 1997 for approximately $187 million (net of cash acquired). Lay, leveraging his experience from PharMingen's success in developing high-quality monoclonal , established BioLegend to continue advancing tools for biomedical research in a post-acquisition market landscape. The company started with a modest team and focused initially on filling unmet needs in the sector, where demand for reliable reagents was growing amid expanding research into immune responses and . From its inception, BioLegend's operations centered on manufacturing purified and fluorophore-conjugated monoclonal antibodies tailored for immunological applications, such as and cell analysis. This hands-on approach allowed the company to produce with consistent quality and specificity, targeting researchers in academic and biotech settings. The early prioritized affordability and accessibility to counter the higher pricing from established giants like BD Biosciences, enabling smaller labs to access advanced tools without compromising performance. By emphasizing customer collaboration and rapid product iteration, BioLegend positioned itself as a nimble alternative in a competitive field dominated by larger players. In its formative years, BioLegend overcame challenges including the intensified competition following PharMingen's acquisition, which consolidated among fewer entities, and secured initial private funding of about $262,500 to support operations and scaling. A key early achievement was developing an expanding catalog of over 100 immunology-focused antibodies by the mid-2000s, which built credibility through partnerships with academic laboratories conducting cutting-edge studies. This foundation enabled rapid growth, transforming BioLegend from a startup into a recognized provider of essential by 2005.

Key Milestones and Innovations

In 2011, BioLegend co-developed and launched the Brilliant Violet™ family of dyes in collaboration with Sirigen Group Ltd., introducing a polymer-based fluorescent that provided brighter signals and reduced spillover in multicolor applications. This innovation enabled researchers to expand panel complexity beyond traditional organic dyes, marking a significant advancement in immunological analysis. By 2014, BioLegend expanded its offerings through the acquisition of Covance Antibody Services Inc., integrating over 1,000 specialized products focused on and research. This move broadened the company's portfolio beyond its core, incorporating custom development capabilities and enhancing its position in broader biomedical applications. During the mid-2010s, BioLegend sustained its growth through continued sponsorships of major events, maintaining platinum status with the American Association of Immunologists annual meeting since 2008 and supporting conferences like IMMUNOLOGY 2010. Parallel to this, the company pursued facility expansions in , including renovations to existing spaces and planning for larger infrastructure to accommodate increasing demand. From 2017 to 2019, BioLegend released innovative tools such as LEAF™ purified antibodies, designed for low-endotoxin, azide-free applications in functional assays and in vivo studies. The company also expanded into cell separation technologies with the introduction of the MojoSort™ magnetic bead-based system, enabling efficient positive and negative selection of immune cell subsets from complex samples. In 2020, BioLegend opened its new state-of-the-art campus in , a multi-building facility emphasizing the iACT culture of innovate, aspire, collaborate, and transform to foster employee collaboration and research efficiency. That year, the company released the documentary "From Research to Cure," highlighting its mission to support scientific breakthroughs from to therapeutic applications. These developments contributed to BioLegend's portfolio expanding to thousands of reagents by 2020, solidifying its leadership in providing both custom and off-the-shelf antibodies and tools for immunological and related biomedical research.

Acquisition and Integration

On July 26, 2021, announced an agreement to acquire BioLegend for approximately $5.25 billion in a combination of cash and stock, highlighting synergies in life sciences tools and diagnostics to strengthen their combined offerings. The deal was driven by BioLegend's expertise in high-margin antibodies and , which complemented PerkinElmer's instrumentation and services, particularly in expanding capabilities for research and applications. The acquisition was completed on September 17, , marking PerkinElmer's largest transaction to date and expected to contribute about $380 million in revenue for BioLegend in fiscal 2022, along with an adjusted accretion of $0.30 in the first full year post-close. Integration efforts focused on preserving BioLegend's operational independence, with its headquarters designated as PerkinElmer's global for reagents, ensuring continuity in activities. The BioLegend brand was retained to maintain customer trust and market presence, while opportunities for emerged with PerkinElmer's established lines, such as Euroimmun diagnostics. In 2023, underwent a corporate restructuring, spinning off its applied, food, and enterprise services businesses and rebranding the remaining life sciences and diagnostics segment as , with positioned as a product line alongside ViaCord and Diagnostics. This transition emphasized 's focus on innovative solutions in health sciences, integrating 's portfolio without altering its core identity. Following the acquisition, BioLegend benefited from increased R&D resources and expanded global distribution through Revvity's sales infrastructure, fostering accelerated product development in high-growth areas like biologics while upholding operational autonomy and avoiding significant disruptions to its established workflows. These enhancements supported immediate revenue synergies, projected to reach $100 million annually by the fifth year, primarily through combined customer access and innovation pipelines. Under Revvity, BioLegend continued to innovate, including a November 2024 collaboration with Scale Biosciences to launch a solution for high-parameter protein profiling of single cells using TotalSeq™-A antibody panels, and the introduction of new StarBright Dye UV laser options in early 2025.

Products and Services

Core Antibody Portfolio

BioLegend's core antibody portfolio primarily consists of monoclonal antibodies designed for high specificity and reproducibility in immunological research. These antibodies are available in various formats, including purified forms for general use and conjugated variants labeled with fluorophores such as and to facilitate multicolor detection. They support key applications like for cell phenotyping, for tissue analysis, and for cytokine quantification. The portfolio encompasses an extensive collection of over 28,000 in-house validated monoclonal and polyclonal antibodies, targeting a wide array of immune cell markers (such as CD45 for pan-leukocyte identification), cytokines (including IL-2 and TNF-α), and signaling molecules (like NF-κB pathway components). This breadth emphasizes rigorously tested clones to ensure experimental reproducibility, with validation data—including knockout/knockdown confirmation—provided in product catalogs and datasheets. For instance, antibodies against activation markers like CD69 and CD25 enable detailed studies of T-cell responses and immune modulation. Customization services allow researchers to request conjugate development, such as adding specific fluorophores or isotopes, and bulk scaled to experimental needs, ensuring tailored solutions without compromising quality. Quality standards are maintained through options like the LEAF™ (Low Endotoxin, Azide-Free) series, which features endotoxin levels below 0.1 EU/μg and no preservatives, making them suitable for applications such as animal models of . The Ultra-LEAF™ variant further reduces endotoxins to under 0.01 EU/μg for highly sensitive functional assays. Originally centered on since BioLegend's founding in 2002, the portfolio has evolved to incorporate comprehensive coverage of pan-leukocyte and immune activation markers, reflecting advancements in understanding leukocyte diversity and functional states. This progression supports broader workflows in and has been enhanced by innovations like the 2011 launch of Brilliant Violet dyes for expanded panels.

Reagents and Kits

BioLegend offers a range of non-antibody and designed to support various stages of life science research, including , detection, and workflows. These products provide complete solutions with optimized buffers, standards, and detailed protocols to ensure and in experiments such as immune monitoring and cell characterization. Assay kits from BioLegend include ready-to-use formats and multiplex systems for and quantification. The LEGENDplex™ kits are bead-based immunoassays compatible with standard cytometers, featuring pre-coated fluorescent beads for simultaneous detection of multiple analytes, such as in panels that measure up to 13 with enhanced and compared to traditional . These kits supply all necessary components, including capture beads, detection reagents, standards, and buffers, along with validated protocols for , , or supernatants. Single-plex and multi-plex kits similarly provide pre-coated 96-well plates, standards, and buffers for streamlined workflows in detection and cell viability assessment. Cell viability assays, such as the Cell Viability™ Kit, utilize reduction to quantify in real-time, while Zombie™ fixable dyes (e.g., Zombie Aqua™ or Violet™) enable discrimination of live and dead cells in fixed samples via amine-reactive labeling of compromised membranes. Cell separation tools, particularly the MojoSort™ system, facilitate of specific immune cell subsets using magnetic nanobead technology. These kits employ biotinylated selection cocktails combined with nanobeads for positive or negative selection, yielding untouched populations such as T cells (e.g., CD3+ or +), B cells, cells, monocytes, or stem cells from peripheral blood mononuclear cells or lymphoid tissues. The process involves brief incubations (5-15 minutes) followed by on columns, supporting high-purity without specialized equipment beyond standard magnets. MojoSort™ kits include all buffers and protocols for scalable applications in and bioprocessing. Ancillary reagents complement these workflows with optimized buffers, blockers, and fixatives tailored for , imaging, and intracellular staining. The Fixation Buffer, formulated with low-background , preserves cell morphology for intracellular (ICFC) and (ICC), paired with Permeabilization Wash Buffer for target access. Cell Staining Buffer and blocking reagents minimize non-specific binding, while FluoroFix™ Buffer stabilizes fluorescent signals in fixed samples, particularly for tandem dyes. For manufacturing, BioLegend's Cell-Vive™ GMP portfolio provides cGMP-compliant ancillary materials, including serum-free media supplements, recombinant proteins like , and reagents produced in ISO 13485-certified facilities to meet and Ph. Eur. standards. Following the 2014 acquisition of Covance Antibody Products, BioLegend expanded its offerings in and with additional reagents for studies and neuronal applications. This integration introduced GMP-grade components like recombinant for and matrix remodeling assays, enhancing support for high-throughput and research in these fields. These kits and reagents are widely used in academic and pharmaceutical settings for scalable screening, enabling precise analysis in immune-oncology, development, and .

Specialized Technologies

BioLegend has developed several proprietary technologies that advance , , and applications, enabling researchers to perform high-resolution studies of immune responses and cellular phenotypes. One of the cornerstone innovations is the Brilliant Violet™ family of dyes, introduced in 2011 as polymer-based tandem fluorochromes excited by violet lasers (typically 405 nm). These dyes exhibit exceptional brightness—up to 50-fold greater than conventional fluorophores like Pacific Blue—and superior photostability, allowing for the construction of multicolor panels exceeding 20 parameters in with reduced spillover and minimal compensation requirements due to their narrow emission spectra. This technology has become integral for dissecting complex immune cell subsets, as demonstrated in protocols optimized for violet-excitable instruments from partners like Cytek Biosciences and . Complementing these dyes, BioLegend's TotalSeq™ platform consists of oligonucleotide-conjugated antibodies designed for cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), facilitating simultaneous detection of surface proteins and mRNA transcripts at the single-cell level. TotalSeq™ reagents, available in variants A, B, and C to match different capture chemistries (e.g., poly(dT) or feature barcoding with 10x Genomics workflows), integrate seamlessly into RNA-seq pipelines, providing high-sensitivity protein data with low background noise. This multiomics approach has proven essential for mapping tumor microenvironments and immune cell heterogeneity in cancer studies, where protein-level insights reveal functional states not captured by transcriptomics alone. Additional specialized tools include the True-Nuclear™ Transcription Factor Buffer Set, a fixation and permeabilization system optimized for intracellular staining of nuclear proteins like , while preserving surface marker integrity and stability. BioLegend employs CRISPR-based and knockdown models to confirm specificity and offers spatial reagents tailored for multiplexed tissue platforms such as MERFISH and NanoString GeoMx, supporting analysis of protein distributions in tumor tissues. The company's R&D emphasizes low-background, high-sensitivity innovations, including collaborations with instrument manufacturers like and Pleno for enhanced compatibility in single-cell and workflows. These technologies collectively empower intricate experiments in and , with detailed protocols available in peer-reviewed literature and BioLegend's resources, accelerating discoveries in modulation and personalized cancer therapies.

Operations

Manufacturing and Facilities

BioLegend's primary manufacturing facility is a state-of-the-art campus located in , , which opened in 2019 and spans advanced cleanrooms equipped with automation systems dedicated to antibody production. This $100 million investment includes laboratory spaces, renovated buildings, and integrated infrastructure designed to support high-volume reagent manufacturing. The company also maintains research and development sites in and . The company's production processes encompass in-house monoclonal antibody development, beginning with hybridoma generation and clone selection based on criteria such as growth robustness and antibody yield, followed by purification via and conjugation with fluorochromes or other labels under optimized conditions. These processes are scalable, enabling production from research-grade antibodies to GMP-compliant materials suitable for clinical applications, all conducted within a dedicated GMP facility. Quality assurance at BioLegend is governed by an :2016-certified management system, which ensures rigorous lot-specific testing for purity exceeding 95%, specificity through methods like , and functionality via assays such as and immunofluorescent staining. Traceability is maintained through detailed certificates of analysis provided for each lot, supporting reproducibility and compliance in biomedical research. The San Diego campus provides substantial capacity to meet global demand, with integrated R&D laboratories facilitating and process optimization alongside production. Post-2023 integration with , BioLegend's operations incorporate eco-friendly practices, including waste minimization and energy-efficient systems aligned with Revvity's sustainability goals of reducing Scope 1 and 2 by 50% by 2033.

Global Reach and Distribution

BioLegend maintains its headquarters in , , , with subsidiaries and direct operations in key international locations to support its global footprint. These include BioLegend Europe B.V. in , , which handles distribution across much of ; BioLegend in , , providing sales and technical support; BioLegend Japan K.K. in , ; and BioLegend (Beijing) Ltd. in , . Warehouses in , , and , , facilitate efficient logistics, enabling direct sales and distribution in over 50 countries through a network of authorized distributors. The company's distribution model emphasizes accessibility via its platform at biolegend.com, where customers worldwide can place orders, with regional websites supporting multiple languages such as English, German, Japanese, and Chinese. Partnerships with major laboratory suppliers like and VWR enhance availability, allowing seamless integration into global supply chains for academic, pharmaceutical, and (CRO) customers. In , compliance with regulations such as REACH is ensured through its local subsidiaries, while distributors like Biomedica and Nordic Biosite cover specific markets, and in Asia, partners such as Biogene India and Genomax Technologies serve regions including and . This structure supports thousands of laboratories annually across sectors like , biotech, and pharma. Customer engagement extends through active participation in international conferences, including sponsorships and travel awards for events like CYTO 2025 and SITC 2025, where BioLegend offers workshops, poster sessions, and product promotions to foster direct interaction with researchers. Literature resources, such as multilingual catalogs and webinars on applications like , are available via the company website to aid global users. Following its 2021 acquisition by (formerly ), BioLegend has leveraged the parent company's extensive network to accelerate delivery times and provide localized , enhancing penetration in emerging biotech hubs in and .

References

  1. [1]
    Our Company | BioLegend
    **Summary of BioLegend:**
  2. [2]
    BioLegend - Crunchbase Company Profile & Funding
    BioLegend is a biotechnology firm that offers immunological reagents for biomedical research. The company develops world-class, cutting-edge antibodies.
  3. [3]
    BioLegend Careers, Perks + Culture - Built In
    BioLegend was incorporated in June, 2002. The founder and CEO of BioLegend, Gene Lay, D.V.M., who was also the co-founder of PharMingen.Missing: history | Show results with:history
  4. [4]
    Watch Video: A History of BioLegend - Biocompare
    Mar 23, 2017 · BioLegend was established in San Diego, CA in 2002 by Gene Lay, a co-founder of PharMingen. In 2002, we began manufacturing purified and fluorophore-conjugated ...
  5. [5]
    Celebrating a Historic $100 Million Gift to Establish The Gene Lay ...
    Since its founding in 2002, BioLegend has expanded its reach across the globe, with research and development facilities in Taiwan and Japan, as well as ...<|separator|>
  6. [6]
    PerkinElmer Completes Acquisition of Antibody and Reagent ...
    Sep 17, 2021 · PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend. September 17, 2021. Download (opens in new window) · PDF Version.
  7. [7]
    WilmerHale Represents PerkinElmer in $5.25B Acquisition of ...
    Jul 26, 2021 · On July 26, 2021, PerkinElmer, a global leader committed to innovating for a healthier world, announced it has entered into an agreement to ...Missing: Revvity date
  8. [8]
    BioLegend 2025 Company Profile: Valuation, Investors, Acquisition
    Operator of a biotechnology company specializing in biomedical antibodies. The company develops antibodies and reagents like flow cytometry, cell biology and ...
  9. [9]
    Watch Video: A History of Immunology and BioLegend - Biocompare
    Mar 23, 2017 · BioLegend was established in San Diego, CA in 2002 by Gene Lay, a co-founder of PharMingen. In 2008, we became a platinum sponsor of the ...
  10. [10]
    PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
    Jul 26, 2021 · PerkinElmer to Acquire Antibody and Reagent Leader BioLegend · July 26, 2021 at · 8:00 a.m. Eastern Time . To access the call, please dial 720-405 ...
  11. [11]
    https://news.revvity.com/press-announcements/press-releases/press-release-details/2021/PerkinElmer-to-Acquire-Antibody-and-Reagent-Leader-BioLegend-07-26-2021/default.aspx
  12. [12]
    [PDF] IVD and ASR Reagents - BioLegend
    BioLegend products are manufactured in an ISO 13485:2016-certified facility to ensure the highest quality standards. BioLegend provides In Vitro Diagnostic ( ...
  13. [13]
    PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
    Jul 26, 2021 · PerkinElmer today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.
  14. [14]
    Launching Revvity: A Scientific Solutions Company Powering ...
    May 9, 2023 · Revvity Omics replaces PerkinElmer Genomics as the Company's genomics services business. Cisbio, Horizon Discovery, Nexcelom Bioscience ...
  15. [15]
    PerkinElmer's life science and diagnostics spinoff rebrands as Revvity
    May 11, 2023 · Meanwhile, Revvity's scientific software platform, previously known as PerkinElmer Informatics, will be rebranded as Revvity Signals Software, ...
  16. [16]
    Our Brands - Revvity
    Revvity Brands · Biolegend logo. Explore our suite of reagents for flow cytometry, multiomics, C & GT, and immunoassays. · Euroimmun logo. Complete diagnostic ...
  17. [17]
    About Us | BioLegend
    ### Summary of BioLegend
  18. [18]
    News and Events - BioLegend
    Gene Lay founded BioLegend in 2002 and continues to serve as the President and CEO.Missing: history | Show results with:history
  19. [19]
    Life science entrepreneur Gene Lay joins Scripps Research Board ...
    Jan 3, 2024 · Lay is the founder, president and CEO of BioLegend, a global life science company based in San Diego. BioLegend focuses on the development ...
  20. [20]
    BioLegend Management Team | Org Chart - RocketReach
    BioLegend employs 673 employees. The BioLegend management team includes Gene Lay (President and CEO), Kim Clark (VP of Human Resources), and Jim Schindler ...
  21. [21]
    BioLegend - PharmaCompass.com
    BioLegend// The well-being of our employees is of highest importance. Our associates are empowered under our “iACT” culture to Innovate, Aspire, Collaborate ...
  22. [22]
    [PDF] Unlocking Legendary Discovery
    Jul 26, 2021 · This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation.
  23. [23]
    PharMingen, Becton Dickinson deal - BioCentury
    Apr 14, 1997 · Becton Dickinson acquired PharMingen, a manufacturer and marketer of antibodies and reagents for immunology, cell biology and molecular biology research.
  24. [24]
    Nimble by Design: BioLegend's Collaborative Approach to Business
    BioLegend. Specialties, Biomedical research, immunology. Mission, To accelerate research and discovery by providing the highest quality products (such as ...Missing: statement | Show results with:statement
  25. [25]
    Gene Lay, founder of BioLegend, turned $262,500 into nearly 300 ...
    Jan 25, 2024 · Discover the incredible journey of Gene Lay, the founder of BioLegend, who turned an initial investment of $262,500 into nearly 300 times ...
  26. [26]
    BioLegend Releases Brilliant Violet 421(TM) Antibody Conjugates ...
    Apr 14, 2011 · BioLegend Releases Brilliant Violet 421(TM) Antibody Conjugates for Advanced Flow Cytometry Applications. April 14, 2011 |. 1 min read. Twitter ...
  27. [27]
    Fluorophores for Multi-Color Flow Cytometry | Biocompare
    Nov 15, 2022 · “BioLegend's introduction of the Brilliant Violet™ fluorophore family in 2011 allowed researchers to create more advanced multicolor panels ...
  28. [28]
    BioLegend Acquires the Antibody Products Business Unit from ...
    Sep 2, 2014 · BioLegend acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.
  29. [29]
    BioLegend Acquires Antibody Products Business Unit From Covance
    Sep 2, 2014 · San Diego-based BioLegend Inc. acquired the shares of Covance Antibody Services Inc., a business unit of Massachusetts-based Covance Inc., ...
  30. [30]
    IMMUNOLOGY 2010TM -- 97th AAI Annual Meeting Scientific ...
    AAI Awards being presented at AAI's 97th Annual Meeting, IMMUNOLOGY 2010 ... This reception is very generously sponsored by BioLegend. AAI COMMITTEE-SPONSORED ...
  31. [31]
    BioLegend Campus Expansion - DPR Construction
    A new biotech campus in San Diego for BioLegend, an award-winning project that completed ahead of schedule and 2% under budget.
  32. [32]
    Ultra-LEAF™ Purified anti-mouse CD28 Antibody - BioLegend
    Version : 1 Revision Date : 11/30/2012. Ultra-LEAF™ Purified anti-mouse CD28 Antibody. Pricing & Availability · Product Details · Antigen Details ...
  33. [33]
    Bio-Bits - MojoSort™ Magnetic Cell Separation System - BioLegend
    We are proud to introduce MojoSort™, a magnetic bead-based system for effective cell isolation. Cells can be isolated through positive selection, ...Missing: technologies 2019
  34. [34]
    [PDF] MojoSort™ Selection Kits Column Protocol - 3
    Oct 1, 2019 · BioLegend MojoSort™ nanobeads work in commonly used separation columns, based on our internal research as well as validation by external testing ...
  35. [35]
    BioLegend's New $100M Campus Reflects Mission
    Oct 18, 2020 · A Sorrento Valley life science company – BioLegend – has built a new campus that cost more than $100 million. Designed by Delawie architects ...
  36. [36]
    From Research to Cure, BioLegend Documentary - YouTube
    Jan 7, 2020 · It also presents BioLegend's iACT culture dedicated to innovate, aspire, collaborate, and transform ... It also presents BioLegend's iACT culture ...
  37. [37]
    https://www.sdbj.com/uncategorized/biolegends-new-100m-campus-reflects-mission/
  38. [38]
    pki-20220102 - SEC.gov
    BioLegend's acquisition provides us with access to new markets as well, notably the flow cytometry and multiomic cell analysis markets. We also provide services ...
  39. [39]
    PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
    PerkinElmer today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.
  40. [40]
    PerkinElmer to Acquire Antibody, Reagent Maker BioLegend for ...
    Jul 26, 2021 · PerkinElmer said today it agreed to acquire BioLegend, a provider of life science antibodies and reagents, for approximately $5.25 billion ...Missing: details | Show results with:details
  41. [41]
    PerkinElmer Completes Acquisition of Antibody and Reagent ...
    Sep 17, 2021 · PerkinElmer today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and ...Missing: July | Show results with:July
  42. [42]
    PerkinElmer's Life Science and Diagnostics business becomes ...
    May 10, 2023 · PerkinElmer's Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions ...
  43. [43]
    Primary Antibodies
    ### Summary of BioLegend's Core Antibody Portfolio
  44. [44]
    https://www.ddw-online.com/perkinelmers-life-science-and-diagnostics-business-becomes-revvity-23577-202305/
  45. [45]
    https://news.revvity.com/press-announcements/press-releases/press-release-details/2024/Scale-Biosciences-and-Revvitys-BioLegend-Launch-First-of-its-Kind-Solution-for-High-Parameter-Protein-Profiling-of-Single-Cells/default.aspx
  46. [46]
    [PDF] LEAF™ and Ultra-LEAF™ (Low Endotoxin, Azide-Free ... - BioLegend
    LEAF™ and Ultra-LEAF™. (Low Endotoxin, Azide-Free) Biofunctional Antibodies. Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343). Tel: 858.768.5800.
  47. [47]
    [PDF] BioLegend - Immunoassays
    These ready-to-use kits contain all of the required reagents, including a 96-well strip plate pre- coated with capture antibody. The kits are validated in both ...
  48. [48]
    LEGENDplex™ - BioLegend
    LEGENDplex™ allows researchers to quantify cytokines on most common flow cytometers. It utilizes beads pre-coated with antibodies for their intended target.LEGENDplex™ Human Panels · Panel Wizard · Support · Resources
  49. [49]
    Zombie Aqua Fixable Viability Kit - BioLegend
    Description. Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes.
  50. [50]
    MojoSort Mouse CD3 T Cell Isolation Kit - BioLegend
    A single cell suspension from C57BL/6 mouse lymphoid tissues was prepared to isolate CD3+ T cells using the MojoSort™ Mouse CD3 T Cell Isolation Kit.
  51. [51]
    MojoSort™ Human CD8 T Cell Isolation Kit - BioLegend
    Non CD8 + T cells are depleted by incubating your sample with the biotin antibody cocktail followed by incubation with magnetic Streptavidin Nanobeads.
  52. [52]
    Fixation Buffer - BioLegend
    BioLegend's Fixation Buffer has been formulated with prescreened paraformaldehyde with low background, thus producing the greatest signal to noise ratio.Missing: ancillary | Show results with:ancillary
  53. [53]
    [PDF] Flow Cytometry Buffers and Solutions - BioLegend
    BioLegend provides a variety of rigorously validated buffers to help you achieve exemplary staining, including Fc receptor and monocyte blocking reagents, ...Missing: ancillary | Show results with:ancillary<|separator|>
  54. [54]
    FluoroFix Buffer - BioLegend
    FluoroFix™ Buffer is a ready-to-use buffer, specially formulated for fixation of immunofluorescence stained cells, optimized to stabilize tandem dyes. It can be ...Missing: ancillary | Show results with:ancillary
  55. [55]
    Cell-Vive™ GMP Portfolio - BioLegend
    Our GMP solutions page allows you to browse our extensive catalog of GMP reagents that support cell research and cell and gene therapy.
  56. [56]
    Cell-Vive™ GMP Recombinant Human FN-1 (carrier-free) - BioLegend
    Fibronectin (FN) is an adhesive glycoprotein found as insoluble components of the extracellular matrix (ECM) or as soluble dimeric forms in plasma.
  57. [57]
    [PDF] GMP Reagents - BioLegend
    GMP reagents are produced under cGMP for cell bioprocessing, manufactured in a dedicated facility, and compliant with ISO 13485:2016, but not for therapeutic ...
  58. [58]
    Brilliant violet fluorophores: A new class of ultrabright fluorescent ...
    Apr 6, 2012 · These “Brilliant Violet” reporters are dramatically brighter than other UV-violet excitable dyes, and are of similar utility to phycoerythrin (PE) and ...
  59. [59]
    What is the difference between TotalSeq A, B, and C? - 10x Genomics
    Nov 3, 2025 · AI summary: BioLegend's TotalSeq A, B, and C antibodies differ in capture sequences and compatibility: TotalSeq A suits poly(dT)-based ...
  60. [60]
    Pleno Deploys its RAPTOR Instrument Platform Available with
    Jan 8, 2024 · Pleno and BioLegend have collaborated to integrate their technologies, facilitating a streamlined approach for customers to enable ...
  61. [61]
    Product Development - BioLegend
    BioLegend develops reagents like proteins and antibodies. Antibody development includes clone selection, application testing, and validation in knockout/ ...<|separator|>
  62. [62]
    Cell-Vive™ Quality - BioLegend
    Are manufactured in an ISO 13485:2016 certified GMP manufacturing facility. · Adhere to strict manufacturing guidelines.
  63. [63]
    PE anti-mouse IgE Antibody - BioLegend
    Jan 26, 2017 · The RME-1 monoclonal antibody reacts with immunoglobulin E (IgE) in all tested mouse haplotype (Igh-a and b). It does not react with other isotypes.Missing: house | Show results with:house
  64. [64]
    Our Company - BioLegend
    BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.
  65. [65]
    [PDF] C E R T I F I C A T E - BioLegend
    Dec 15, 2022 · ISO 13485:2016. Regulatory Authority(ies):. Health Canada, USA FDA. See ... Manufacturing, Quality Control, Quality Assurance,. Facilities ...
  66. [66]
    Purified Mouse IgE, κ Isotype Ctrl Antibody - BioLegend
    Nov 30, 2012 · Each lot of this antibody is quality control tested by ELISA and SAS-PAGE to assure the isotype and purity, and the purity is greater than 95%.
  67. [67]
    Certificate of Analysis - BioLegend
    Enter the Lot# of the product you have purchased from BioLegend in the field below to review lot-specific CoA.Missing: assurance purity
  68. [68]
    TotalSeq™-A0014 anti-mouse/human CD11b Antibody - BioLegend
    Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis and the oligomer sequence is confirmed by ...
  69. [69]
    BioLegend Campus - Delawie | Architecture & Interior Design
    A campus-like environment that would foster a sense of collaboration and dedication to the biotech company's mission to enable Legendary Discovery.
  70. [70]
    [PDF] Advancing science and sustainability. - Revvity
    Revvity recognizes action is needed to address ongoing sustainability challenges in our manufacturing facilities and lab operations, as well as those of our ...Missing: capacity | Show results with:capacity
  71. [71]
    Revvity, Inc. - Sustainability Overview
    What are Revvity's corporate Sustainable Business Goals? · To reduce the Company's Scope 1 and 2 greenhouse gas emissions by 50% by 2033 · Achieve 40% non- ...Missing: BioLegend capacity
  72. [72]
    Worldwide Ordering
    ### Summary of BioLegend's Global Distribution Network
  73. [73]
    News - BioLegend
    BioLegend, leading provider of world-class biological reagents and tools that enable life science discovery from research to cure, today announced the opening ...
  74. [74]
    Biolegend Purified anti-EGFR, Quantity: Each of 1 | Fisher Scientific
    Count on us for an unrivaled selection of lab, life sciences, safety, and facility management supplies—including chemicals, equipment, instruments, diagnostics, ...
  75. [75]
    Events
    ### BioLegend’s 2025 Conference Participation